SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as the community highlights its unique Layer 0 architecture and real-world utility in data infrastructure, particularly its active collaboration with the U.S. Department of Defense and recent acquisition by an AI-focused holding company. Investors are actively discussing the project's long-term enterprise potential, cross-chain integrations with Base, and the impact of its Tessellation v3.0 network upgrades on scalability.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN CRYPTO community is intensely polarized, with some members hyping the coin as a 'weekend runner' poised for massive gains, while a vocal contingent dismisses it as a 'scam' and 'rug pull' tied to the controversial history of its corporate namesake. Despite the persistent skepticism regarding its legitimacy, the community remains hyper-focused on social media trends, bot-driven volume, and speculative 'community takeover' narratives.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor attention as the community closely monitors the development of its lead hidradenitis suppurativa candidate, AVTX-009, with upcoming Phase 2 data acting as a key catalyst. Discussions are heavily focused on the stock's high volatility and massive volume spikes, with participants debating its long-term potential versus concerns regarding ongoing funding needs and clinical execution risks.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as community members weigh the brand's rapid expansion into physical retail and gaming against concerns over recent price volatility. While supporters highlight the potential for long-term growth driven by tangible revenue and major marketing efforts like the Las Vegas Sphere campaign, others are debating whether current market conditions and broader sector pressure represent an accumulation opportunity or a signal of further downside.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing attention as developers and institutional investors focus on its role in providing essential Web3 data indexing for AI and decentralized protocols. While some community members remain frustrated by price volatility and historical dilution, bulls are aggressively accumulating the asset, citing its integration with major blockchains and expectations for infrastructure-led growth.

Maul Coin

Maul Coin is generating significant buzz as a community-driven project that is rallying its supporters to push for increased visibility and a breakout move. The community remains highly active in defending the token against bot manipulation and profit-taking, while focusing on long-term growth and potential exchange listings.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

JNUG is seeing heightened volatility as traders weigh record-breaking precious metal prices against community concerns regarding market overextension and the potential for a technical correction. Investors are intensely focused on shifting monetary policy expectations and the broader macroeconomic impact of increased government spending.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is currently in the spotlight following the FDA's issuance of a Complete Response Letter regarding the manufacturing vendor for its lead candidate, oxylanthanum carbonate, which has led to a delay in the approval process. While investors are expressing frustration over the lack of a clear timeline and recent share price volatility, many in the community remain bullish on the long-term potential of the drug, citing its strong clinical data and best-in-class pill burden profile as key reasons to maintain their positions.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant traction as a critical DeFi infrastructure provider, fueled by its role in supplying institutional-grade data and macroeconomic indicators from the U.S. government to various blockchains. Community sentiment remains bullish due to the project's real-world utility, revenue-backed token buyback program, and its central position in the growing Real World Asset narrative.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

The ProShares UltraPro Short QQQ (SQQQ) is seeing heightened activity as market participants navigate intensifying geopolitical tensions and growing skepticism toward the sustainability of the AI sector. The community is actively debating the potential for a broader market downturn, with traders utilizing the instrument to hedge against volatility and speculation surrounding economic stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Russell 2000 Value ETF (IWN) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The weakness in revenue was led by the Services segment, which declined 9% due to weakness in construction revenue.</li><li>The company’s net income from continuing operations attributable to company stockholders totaled $1.16 per diluted share, compared to $1.12 per diluted share in 2024.</li><li>Retail revenue jumped year over year, driven by an 8.3% increase in water volume sold, to a record 1.09 billion gallons.</li></ul>Consolidated Water (CWCO) stock fell 16% during extended hours of trading on Monday after its fourth-quarter (Q4) results disappointed investors.&nbsp;The company reported a 1% decline in total revenue to $132.1 million in FY 2025, well short of analysts’ estimates of $137.9 million, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>. The weakness in revenue was led by the Services segment, which declined 9% to $46.3 million, primarily due to weakness in construction revenue.“Our retail, bulk and manufacturing revenues and operating incomes in 2025 were consistent with our expectations,” commented Consolidated Water CEO, Rick McTaggart.&nbsp;“However, our services revenue from continuing operations did not meet our expectations due to a permitting delay related to our 1.7 million gallon per day seawater desalination plant project in Kalaeloa, Hawaii. We believe that this type of delay is common for the complex, multi-agency permitting process required for a project of this scale and is not due to any failures on the part of Consolidated Water,” McTaggart added.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company’s net income from continuing operations totaled $18.6 million, or $1.16 per diluted share, compared to $17.9 million, or $1.12 per diluted share, in 2024.Retail revenue jumped year over year to a record 1.09 billion gallons, driven by an 8.3% increase in water volume sold. This increase resulted from significantly lower rainfall on Grand Cayman and a 6.6% increase in the number of customer accounts in the company’s license area, the company said.&nbsp;“The continued strength of the Cayman Islands economy and historically low rainfall in our exclusive utility service area on Grand Cayman resulted in our retail segment revenue increasing about 6% compared to the previous year,” McTaggart further said.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around CWCO stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 14% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around CWCO stock trended in ‘bullish’ territory amid ‘extremely high’ message volume. 

CWCO Stock Dives 16% After-Hours On FY25 Revenue Miss

The company reported a decline of 1% in its total revenue of $132.1 million in FY 25.

Equity

The company reported a decline of 1% in its total revenue of $132.1 million in FY 25.


<ul class="summary-bullets"><li>Esperion highlighted future growth plans, including expanding U.S. market penetration and advancing its oral triple-combination program.</li><li>The company said that its acquisition of Corstasis Therapeutics also advances its Vision 2040 strategy.</li><li>Esperion also added that it plans to expand geographically through continued collaboration with its global partners.</li></ul>Esperion Therapeutics Inc. (ESPR) shares fell more than 6% in Tuesday morning’s trade after the company reported a mixed fourth quarter.Esperion reported earnings per share (EPS) of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million, according to Fiscal.ai data.“2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin-intolerant or statin-resistant patients, and strengthened the durability of our business with important intellectual property and market access advances,” said Esperion CEO Sheldon Koenig.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ESPR">Esperion</a> trended in the ‘extremely bullish’ territory despite the mixed fourth-quarter (Q4) performance. Message volumes were at ‘extremely high’ levels at the time of writing.One bullish user stated that the ESPR stock appears way undervalued.<stembedurl>https://stocktwits.com/DP000/message/647094104</stembedurl>Another user stated that Esperion has massive catalysts coming up.<stembedurl>https://stocktwits.com/BRLondon/message/647092901</stembedurl><h2 class="st-heading-2">Esperion Highlights Upcoming Catalysts</h2>Esperion stated that it is investing in several clear catalysts for future growth. These include deeper penetration in the U.S. market supported by strong payer coverage, as well as progress on its oral triple-combination program designed to compete with products currently on the market or in development.The firm also added that it plans to expand geographically through continued collaboration with its global partners.“We are entering 2026 with confidence, discipline, and a long-term mindset focused on creating lasting value for patients, providers, and shareholders,” Koenig added.The company said that it aims to pursue new therapeutic opportunities and develop next-generation inhibitors targeting multiple life-threatening diseases.ACLY is a metabolic enzyme involved in breaking down nutrients and producing cholesterol and fatty acids, making it a potential target for treating a range of diseases.<h2 class="st-heading-2">Koenig Says Corstasis Deal Advances Vision 2040</h2>During a post-earnings call with analysts, Koenig said that the planned acquisition of Cortasis Therapeutics advances the company’s Vision 2040.“The acquisition of Corstasis is a catalyst for additional long-term value and a testament to our commitment to building a larger and sustainably profitable company. Our priority is to grow these two franchises to their multi-billion-dollar potential,” he said.Esperion announced earlier this month that it had entered into an agreement to acquire Corstasis for an upfront payment of $75 million. Corstasis shareholders will also be eligible to receive an additional $180 million upon the attainment of certain regulatory and commercial milestones, as well as royalties on sales of Enbumyst and follow-on products.<a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> is down 21% year-to-date, but up more than 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d">Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

<ul class="summary-bullets"><li>For Q4, Arq reported total revenue of $29.4 million, reflecting an increase of 9%.</li><li>Arq said it has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review.</li><li>The company said that Jay Voncannon will no longer serve as the Company’s Chief Financial Officer, effective immediately.</li></ul>Arq stock plunged 22% during extended hours of trading on Monday after it reported a larger fourth-quarter 2025 loss compared to the year-ago quarter.The company reported a net loss of $52.6 million in FY 2025, versus a net loss of $5.1 million in FY 2024. In Q4 2025, net loss came at $50.0 million, compared to a net loss of $1.3 million in Q4 2024.&nbsp;<h2 class="st-heading-2">Earnings</h2>Arq reported revenue totaling $29.4 million for the fourth quarter of 2025, reflecting an increase of 9% compared to $27.0 million in the prior year period. The increase was driven predominantly by enhanced volumes and pricing.Arq’s gross margin reduced to 13.6% for the fourth quarter of 2025, compared to 36.3% in the prior year period. The reduction in gross margin was driven by higher costs associated with GAC start-up.<h2 class="st-heading-2">GAC Strategy Updates</h2>Arq said it has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review of the path forward for the company’s Granular Activated Carbon (GAC) for water, air, and industrial purification business.This decision comes after independent tests in late January 2026 revealed that the Arq’s existing thermal oxidizer can support only about 15 million pounds of GAC production per year and would need further modifications to reach the initial goal of 25 million pounds or more annually.In bid to transition away from using Corbin Wetcake for its GAC products, Arq is temporarily idling its Corbin facility and in connection recorded a non-cash impairment charge of $45 million in Q4 2025.<h2 class="st-heading-2">CFO Change</h2>The company said that Jay Voncannon will no longer serve as the company’s Chief Financial Officer, effective immediately.Stacia Hansen will serve as the company’s principal financial officer while continuing in her role as Chief Accounting Officer.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ARQ trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 29.3% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arq stock plunged 22% during extended hours of trading on Monday after it reported a larger fourth-quarter 2025 loss compared to the year-ago quarter.

Why Is ARQ Stock Plummeting?

The company reported Q4 2025 net loss of $50.0 million vs. net loss of $1.3 million in Q4 2024. 

<ul class="summary-bullets"><li>Rumble CEO said that the firm has reached an inflection point.</li><li>The company said its loss per share during the quarter was at $0.13, compared to $1.15 per share from the year-ago quarter.</li><li>The loss during the quarter marginally missed analyst estimates of loss of $0.1 per share.</li></ul>Rumble Inc.&nbsp;shares fell nearly 4% in extended hours of trading on Thursday after it reported a 10% decline in fourth-quarter (Q4) revenue compared to the year-ago quarter.&nbsp;Revenue for Q4 was $27.1 million, in line with analyst expectations, as per Fiscal.ai. The revenue was a decrease of 10% from $30.2 million reported in the second quarter of 2024.&nbsp;The decline was attributable to a decrease in Audience Monetization revenues and lower Other Initiatives revenues, the company said.&nbsp;"Rumble has reached an inflection point. The investments we made throughout 2025, in platform stability, creator monetization, short-form video, and our sales infrastructure, are beginning to bear fruit,” said Chris Pavlovski, Rumble's Chairman and CEO.&nbsp;&nbsp;<h2 class="st-heading-2">Results In Detail</h2>Net loss for the fourth quarter was $32.7 million compared to a loss of $236.8 million in the fourth quarter of 2024, principally attributable to a $184.7 million loss in the change in fair value of derivative expense related to Tether's strategic investment in Rumble.The company said its loss per share during the quarter was at $0.13, compared to&nbsp;a loss of&nbsp;$1.15 per share from the year-ago quarter. The loss during the quarter marginally missed analyst estimates of loss of $0.1 per share.The company said that during the fourth quarter, it secured a $100 million advertising commitment from Tether, structured as $50 million per year over two years beginning in Q1 2026. The efforts are designed to advance Rumble Wallet integration, expand creator monetization, and accelerate new advertising solutions on the platform.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RUM stock trended in&nbsp;the ‘bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user predicted that Rumble’s 2026 looks good.&nbsp;<stembedurl>https://stocktwits.com/FredettenWahoo/message/646743733</stembedurl>Another user said that they knew the results will be in line with estimates as the company has declared results early.&nbsp;<stembedurl>https://stocktwits.com/Prostar/message/646743582</stembedurl>Shares in the company have fallen 13.4% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Rumble Inc. 

Rumble Stock Is Diving After Hours – What Happened To Q4 Revenue?

The decline in Q4 revenue was attributable to a decrease in Audience Monetization revenues and lower Other Initiatives revenues. The revenue was in line with analyst expectations, per Fiscal.ai. 

<ul class="summary-bullets"><li>The company saw payment volumes go up by 10% year-over-year to $43.9 billion during the quarter.&nbsp;</li><li>BTIG analyst Andrew Harte said&nbsp;the firm&nbsp;sees&nbsp;an upside in PSFE shares over the next year from leverage reduction.&nbsp;</li><li>BTIG kept a ‘Buy’ rating on the shares.&nbsp;</li></ul>Paysafe stock rallied 22% on Tuesday after it reported&nbsp;an increase&nbsp;in quarterly revenues, prompting financial services firm BTIG to see an uptick in the company's shares over the next year.&nbsp;The company posted&nbsp;a 4% rise&nbsp;in Q4 revenue of $438.4 million,&nbsp;amid an uptick in payment volume, compared to $420.1 million from the year-ago period.<h2 class="st-heading-2">Q4 Snapshot</h2>The company saw payment volumes go up by 10% year-over-year to $43.9 billion during the quarter.&nbsp;Paysafe (PSFE) said that adjusted net income fell to $25.5 million or $0.46 per diluted share versus $29.5 million or $0.48 per share.&nbsp;"Paysafe’s fourth quarter results are consistent with what we outlined in November, and the full year of 2025 marks our third consecutive year of organic revenue growth,” said Bruce Lowthers, CEO of Paysafe.&nbsp;<h2 class="st-heading-2">Outlook For 2026</h2>The company said it sees 2026 revenue in the range of $1.79 billion&nbsp;to $1.83 billion, whose midpoint is in line with the consensus of $1.81 billion, as per data from&nbsp;Fiscal.ai. Paysafe sees 2026 adjusted EPS in the range of $2.12-$2.32. Analysts on average had expected profit of $2.29 per share.&nbsp;“In 2026, we are focused on creating outstanding experiences for both our customers and employees, while targeting higher revenue growth and double-digit adjusted earnings per share growth,” he added.&nbsp;<h2 class="st-heading-2">Analyst Take</h2>BTIG analyst Andrew Harte said&nbsp;the firm sees&nbsp;an upside in PSFE shares over the next year from leverage reduction.&nbsp;However, the analyst lowered the firm's price target on Paysafe to $10 from $11. BTIG kept a ‘Buy’ rating on the shares.&nbsp;The firm said the company's Q4 results were mixed as the Digital Wallet segment beat revenue expectations, while the Merchant Solutions segment missed. BTIG does not expect Paysafe to accelerate growth towards high-single-digit over the medium-term.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on <a href="https://stocktwits.com/symbol/PSFE">PSFE stock</a> trended in&nbsp;the ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 63% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Paysafe sees 2026 revenue in the range of $1.79 billion to $1.83 billion, whose midpoint is in line with the consensus of $1.81 billion, as per data from Fiscal.ai.

Paysafe Rallies As BTIG Sees Upside In Stock Over The Next Year

The company posted Q4 revenue of $438.4 million compared to $420.1 million from the year-ago period. 

<ul class="summary-bullets"><li>The company's total revenue was helped by growth in network services whose revenue represented 19% year-over-year growth. Security revenue showed 32% year-over-year growth.&nbsp;</li><li>Fastly also swung to profit in the fourth quarter compared to the year-ago.</li><li>Fastly said it expects total revenue in the range of $168 million to $174 million for the first quarter of 2026. Analysts expected Q1 2026 revenue of $159.6 million, as per fiscal.ai.&nbsp;</li></ul>Fastly (<a href="https://stocktwits.com/symbol/FSLY">FSLY</a>) shares soared 25% in extended hours of trading on Wednesday after its record fourth-quarter revenue beat estimates.&nbsp;The rally in the stock turned investors bullish on the stock with predictions of the stock to rise 100% by the end of Feb.&nbsp;<a href="https://stocktwits.com/BullyingTheBearss/message/644734186">https://stocktwits.com/BullyingTheBearss/message/644734186</a>The company posted a fourth quarter revenue of $172.6 million that grew 23% year over year. Analysts on average expected revenue of $161.4 million as per data from fiscal.ai.&nbsp;"Our fourth quarter results mark an inflection in Fastly’s growth as we achieved record revenue, gross margin, and operating profit,” said Kip Compton, CEO of Fastly. “In 2025 we made significant progress on Fastly’s transformation and delivered great results.”<h2 class="st-heading-2">Q4 Snapshot</h2>The company's total revenue was helped by growth in network services whose revenue represented 19% year-over-year growth. Security revenue showed 32% year-over-year growth.&nbsp;The company also swung to profit in the fourth quarter compared to the year-ago. It reported adjusted net income per diluted share of $0.12, compared to adjusted net loss per diluted share of $0.02 in the fourth quarter of 2024.The company said it generated $22.4 million of operating cash flow compared to $5.2 million of operating cash flow in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook</h2>Fastly said it expects total revenue in the range of $168 million to $174 million for the first quarter of 2026. Analysts expected Q1 2026 revenue of $159.6 million, as per fiscal.ai.&nbsp;It said its full year-revenue is expected to be in the range of $700 million to $720 million. The higher end of the FY2026 forecast shows 15% growth in full year revenue compared to $624 million it reported for FY2025.&nbsp;It also said it expects adjusted profit to be in the range of $0.07 per share to $0.10 per share for Q1 2026. Analysts on average expected adjusted profit to be $0.01 per share.&nbsp;“As we look toward 2026, we anticipate continued momentum, with AI as an increasing tailwind for our business,” Compton added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around FSLY trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;One user, however, said that Fastly’s earnings did not impress them, except for free cash flow and profitability.&nbsp;<stembedurl>https://stocktwits.com/starwarsjunkie7/message/644734123</stembedurl>Shares in the company have risen 17% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/crypto-token-uni-rises-how-did-blackrock-drive-the-rally/cZb6jCHR4Ad">Crypto Token UNI Jumps 14% - How Did BlackRock Drive The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees work at Fastly's office in San Francisco on Friday, July 20, 2018. 

Why Is Retail Seeing 100% Jump In Fastly’s Stock By Month-End?

The company posted a fourth quarter revenue of $172.6 million that grew 23% year over year. Analysts on average expected revenue of $161.4 million as per data from fiscal.ai. 

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

iShares Trust - iShares Russell 2000 Value ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

IWN
iShares Russell 2000 Value ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWN News

IWNiShares Russell 2000 Value ETF